1672 — Ascletis Pharma Share News
0.000.00%
Last trade - 00:00- HK$6.16bn
- HK$3.50bn
- CNY2.03m
Brief: Ascletis Pharma H1 Net Income RMB -88 Million
Ascletis hits record high on weight loss drug's potential in early trial
Brief: Ascletis Pharma Says ASC47 Showed Greater Efficacy With Tirzepatide
Brief: Ascletis Pharma Inc Says Third-Party Petition Filed Against Company's U.S. Patent
Sagimet soars as oral acne drug aces late-stage trial in China
Brief: Ascletis Pharma Announces Phase III Trial Of Denifanstat Meets All Endpoints
Brief: Ascletis Announces U.S. FDA Clearance Of Ind Application For Its Oral Small Molecule Il-17 Inhibitor, ASC50, For The Treatment Of Psoriasis
Brief: Ascletis Pharma Says US FDA Cleared IND Application For Oral Small Molecule IL-17 Inhibitor, ASC50
Brief: Ascletis Announces First Participants Dosed In A U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, And Semaglutide For The Treatment Of Obesity
Brief: Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist
Brief: Ascletis Pharma Posts FY Net Loss Of RMB300.9 Mln
China's Ascletis hits 6-year peak on good results for weight loss drug
Brief: Ascletis Pharma Announces Positive Phase Ib Results And FDA Clearance
Brief: Ascletis Pharma Inc Updates On ASC47
Brief: Ascletis Announces Promising Phase I Results In Australia For ASC47, Muscle-Preserving Weight Loss Drug for Obesity
Brief: Ascletis Pharma Says Got Initial Determination From US International Trade Commission
Brief: Ascletis Pharma Says Unit's Partner Received U.S. FDA Breakthrough Therapy Designation
Brief: Ascletis Pharma Posts HY Loss Attributable Of RMB130.3 Mln
Brief: Ascletis Pharma Sees HY Net Loss Attributable RMB127.3 Million To RMB132.3 Million